TD Cowen raised the firm’s price target on Natera to $87 from $82 and keeps an Outperform rating on the shares, which the analyst named a “best idea for 2024.” Diligence on the MRD and broader liquid biopsy market provides “fundamental support” to the firm’s 2024 model, which reflects 20%-plus sales growth along with material gross margin improvement, while “numerous organic upside levers plus distinct catalysts” can drive greater than 30% upside to 2026 sales forecasts, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTRA:
- Natera participates in a conference call with JPMorgan
- Morgan Stanley Says These 3 Stocks Are Top Picks for 2024
- Natera enters oncology research agreement with Merck
- Natera upgraded to Strong Buy from Outperform at Raymond James
- Natera raises 2023 revenue outlook to $1.035B-$1.05B, consensus $1.03B
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue